DeLIVER
The Early Detection of
Hepatocellular Liver Cancer
The £2.5 million DeLIVER programme funded by Cancer Research UK is employing cutting-edge technologies and a multidisciplinary approach to enhance early detection methods for hepatocellular carcinoma (HCC), ultimately improving patient outcomes.
Three clinical research studies have been established as part of the DeLIVER programme. These studies will serve as the basis for evaluating early HCC diagnosis technologies and risk stratification methods.
Our Research Studies
-
-
-
Oxford Cancer Information Evening
10 July 2024
Please join us for an online information evening with our liver cancer experts on Thursday 3rd October 5-7pm.
-
-
Funding to compare imaging modalities for liver cancer detection
21 March 2024
The DeLIVER team will evaluate non-contrast-enhanced MRI and compare it to standard of care ultrasound in a cohort of patients under surveillance for liver cancer.
Latest publications
-
Bisulfite-free direct detection of 5-methylcytosine and 5-hydroxymethylcytosine at base resolution
Pub Med
-
Cell-free DNA TAPS provides multimodal information for early cancer detection
-
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy
Pub Med
-
Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations
Pub Med